摘要
以程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂为代表的免疫治疗已经改变了目前胃癌治疗的现状。在晚期胃癌治疗领域,抗人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)治疗仍然活跃,新型药物及其与免疫治疗的联合为HER2阳性患者带来极大的生存获益,靶向Claudin 18.2的细胞免疫治疗为胃癌患者带来新的希望。活跃的转化和基础研究为胃癌患者精准治疗、耐药机制探索提供强大的支持。免疫治疗在局部进展期胃癌中崭露头角,有望形成新的围手术期治疗格局。本文将对2021年度胃癌治疗进展进行盘点和综述。
Programmed death protein-1/programmed death ligand-1 inhibitors profoundly changed the treatment landscape of gastric cancer.As for metastatic gastric cancer,anti-human epidermal growth factor receptor 2 (HER2) therapy is still active.Innovative drugs and their combination with immunotherapy have brought significant survival benefits for HER2 positive patients.On the other hand,cellular immunotherapy targeting Claudin 18.2 brought new hope to gastric cancer patients.Translation and fundamental researches provide great support for gastric cancer precision medicine and give insights into the drug resistance mechanisms.Immunotherapy also showes favorable efficacies in locally advanced gastric cancer,hoping to establish a new pattern for perioperative treatment.Herein,we try to summarize the annual progress in the treatment of gastric cancer in 2021.
作者
谢通
沈琳
Xie Tong;Shen Lin(Department of Gastrointestinal Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处
《肿瘤综合治疗电子杂志》
2022年第1期56-60,共5页
Journal of Multidisciplinary Cancer Management(Electronic Version)
基金
国家自然科学基金重点项目(91959205)。
关键词
胃癌
免疫治疗
细胞免疫治疗
进展
Gastric cancer
Immunotherapy
Cellular immunotherapy
Progress
